PMID- 20023245
OWN - NLM
STAT- MEDLINE
DCOM- 20100311
LR  - 20141120
IS  - 0258-851X (Print)
IS  - 0258-851X (Linking)
VI  - 23
IP  - 6
DP  - 2009 Nov-Dec
TI  - HER2 expression in breast cancer: correlation with endocrine function and 
      psychological status in operable and metastatic breast cancer.
PG  - 987-9
AB  - BACKGROUND: Node involvement, negative estrogen receptor (ER) and HER2 expression 
      are the main negative prognostic factors for breast cancer. Prolactin (PRL) is 
      involved in the control of breast cancer growth and differentiation. 
      Surgery-induced hyperprolactinemia seems to be a positive prognostic factor for 
      operable breast cancer, whereas high PRL levels may predict a poor prognosis in 
      women with metastatic breast cancer. In this study, we evaluated the relation 
      between HER2 expression and PRL blood concentrations in women with metastatic 
      breast cancer women and those whit operable breast cancer patients prior to 
      before and 7 days after surgery. PATIENTS AND METHODS: The study included 50 
      women with breast cancer, 22 of whom had metastatic disease. HER 2 expression and 
      serum levels of PRL were evaluated by fluorescence in situ hybridization (FISH) 
      method and immunoradiometric assay (IRMA) method, respectively. RESULTS: HER2 
      expression occurred in 11/28 operable cases and in 8/22 metastatic cases. The 
      percentage of surgery-induced hyperprolactinemia was significantly higher in 
      HER2-negative patients than in those with its expression. Moreover, HER2-positive 
      metastatic cases showed significantly higher mean serum PRL levels than in the 
      negative group. CONCLUSION: These preliminary results show that metastatic 
      cancer-related hyperprolactinemia and lack of surgery-induced hyperprolactinemia 
      are statistically more frequent in HER2-positive patients, thus suggesting a link 
      between PRL endogenous secretion and HER2 expression in breast cancer.
FAU - Lissoni, Paolo
AU  - Lissoni P
AD  - Institue of Biological Medicine, Milan, Italy. p.lissoni@hsgerardo.org
FAU - Messina, Giuseppina
AU  - Messina G
FAU - Rovelli, Franco
AU  - Rovelli F
FAU - Brivio, Fernando
AU  - Brivio F
FAU - Fumagalli, Luca
AU  - Fumagalli L
FAU - Villa, Silvia
AU  - Villa S
FAU - Bartolacelli, Erio
AU  - Bartolacelli E
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - In Vivo
JT  - In vivo (Athens, Greece)
JID - 8806809
RN  - 0 (DNA, Neoplasm)
RN  - 0 (Receptors, Estrogen)
RN  - 9002-62-4 (Prolactin)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adenocarcinoma/blood/*genetics/secondary
MH  - Breast Neoplasms/blood/*genetics/pathology
MH  - DNA, Neoplasm/analysis
MH  - Female
MH  - Humans
MH  - Hyperprolactinemia/blood/*genetics/pathology
MH  - Immunoradiometric Assay
MH  - In Situ Hybridization, Fluorescence
MH  - Mastectomy/*psychology
MH  - Postoperative Complications/blood
MH  - Postoperative Period
MH  - Prolactin/*blood
MH  - Receptor, ErbB-2/*genetics/metabolism
MH  - Receptors, Estrogen
EDAT- 2009/12/22 06:00
MHDA- 2010/03/12 06:00
CRDT- 2009/12/22 06:00
PHST- 2009/12/22 06:00 [entrez]
PHST- 2009/12/22 06:00 [pubmed]
PHST- 2010/03/12 06:00 [medline]
AID - 23/6/987 [pii]
PST - ppublish
SO  - In Vivo. 2009 Nov-Dec;23(6):987-9.